首页> 美国卫生研究院文献>OncoTargets and therapy >Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung
【2h】

Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung

机译:印度肺腺癌患者EGFR突变和EML4-ALK融合基因的临床和流行病学研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundMutation in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) is a common feature observed in lung adenocarcinoma. A fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the intracellular domain of anaplastic lymphoma kinase (ALK), named EML4-ALK, has been identified in a subset of non-small-cell lung cancer (NSCLC) tumors. The objective of this study was to determine the prevalence of EGFR mutations and EML4-ALK fusions in Indian patients with NSCLC (adenocarcinoma) as well as evaluate their clinical characteristics.
机译:背景表皮生长因子受体(EGFR)酪氨酸激酶结构域的突变是在肺腺癌中观察到的共同特征。已在非小细胞肺癌(NSCLC)肿瘤子集中鉴定了棘皮动物微管相关蛋白样4(EML4)与间变性淋巴瘤激酶(ALK)细胞内结构域之间的融合基因,称为EML4-ALK。 。这项研究的目的是确定印度NSCLC(腺癌)患者中EGFR突变和EML4-ALK融合的发生率,并评估其临床特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号